Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.

Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR; Silymarin in NASH and C Hepatitis (SyNCH) Study Group.

JAMA. 2012 Jul 18;308(3):274-82. doi: 10.1001/jama.2012.8265.

2.

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB.

Nature. 2009 Sep 17;461(7262):399-401. doi: 10.1038/nature08309. Epub 2009 Aug 16.

PMID:
19684573
3.

Pathophysiology of hepatitis C virus infection and related liver disease.

Pawlotsky JM.

Trends Microbiol. 2004 Feb;12(2):96-102. Review.

PMID:
15036326
4.

Acute hepatitis C.

Maheshwari A, Ray S, Thuluvath PJ.

Lancet. 2008 Jul 26;372(9635):321-32. doi: 10.1016/S0140-6736(08)61116-2. Review.

PMID:
18657711
5.

Diagnostic tests for hepatitis C.

Gretch DR.

Hepatology. 1997 Sep;26(3 Suppl 1):43S-47S. Review.

PMID:
9305663
6.

Diagnosis, management, and treatment of hepatitis C: an update.

Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases.

Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759. No abstract available.

PMID:
19330875
7.

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team.

N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912.

8.

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

Cammà C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, Cicchetti A, Colombo GL, Di Marco V, Gasbarrini A, Craxì A; WEF Study Group.

Hepatology. 2012 Sep;56(3):850-60. doi: 10.1002/hep.25734. Epub 2012 Jul 12.

PMID:
22454336
9.

Hepatitis C genotype 4: What we know and what we don't yet know.

Kamal SM, Nasser IA.

Hepatology. 2008 Apr;47(4):1371-83. doi: 10.1002/hep.22127. Review.

PMID:
18240152
10.

Clinical significance of elevated alpha-fetoprotein (AFP) in chronic hepatitis C without hepatocellular carcinoma.

Chen CH, Lin ST, Kuo CL, Nien CK.

Hepatogastroenterology. 2008 Jul-Aug;55(85):1423-7.

PMID:
18795704
11.

Preliminary study of two antiviral agents for hepatitis C genotype 1.

Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C.

N Engl J Med. 2012 Jan 19;366(3):216-24. doi: 10.1056/NEJMoa1104430.

12.

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM.

N Engl J Med. 2013 Jan 3;368(1):34-44. doi: 10.1056/NEJMoa1208953.

13.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators.

Gastroenterology. 2012 Sep;143(3):608-618.e5. doi: 10.1053/j.gastro.2012.05.011. Epub 2012 May 21.

PMID:
22626609
14.

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J.

J Viral Hepat. 2012 May;19 Suppl 2:1-26. doi: 10.1111/j.1365-2893.2012.01590.x. Review.

PMID:
22404758
15.

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.

Welsch C, Jesudian A, Zeuzem S, Jacobson I.

Gut. 2012 May;61 Suppl 1:i36-46. doi: 10.1136/gutjnl-2012-302144. Review. Erratum in: Gut. 2012 Aug;61(8):1145.

PMID:
22504918
16.

Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study.

Vandelli C, Renzo F, Romanò L, Tisminetzky S, De Palma M, Stroffolini T, Ventura E, Zanetti A.

Am J Gastroenterol. 2004 May;99(5):855-9.

PMID:
15128350
17.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
18.

Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis.

Udina M, Castellví P, Moreno-España J, Navinés R, Valdés M, Forns X, Langohr K, Solà R, Vieta E, Martín-Santos R.

J Clin Psychiatry. 2012 Aug;73(8):1128-38. doi: 10.4088/JCP.12r07694. Review.

PMID:
22967776
19.

Antiviral strategies in hepatitis C virus infection.

Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.

J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. Review.

PMID:
22300469
20.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

Supplemental Content

Support Center